Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04147286 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion

Study acronym: StatinTB
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 23, 2024 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jun 30, 2024 to Sep 30, 2025
    • Study completion date: Jun 30, 2026 to Sep 30, 2027
    • Site contact updated
    v4
  2. Primary completion date: Jun 30, 2023 to Jun 30, 2024
    • Study completion date: Jun 30, 2023 to Jun 30, 2026
    • Site contact updated
    v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jun 1, 2022 to Jun 30, 2023
    • Start date changed from estimate of Jan 1, 2020 to Jul 14, 2020
    • Study sites: 0 to 1
    • Study completion date: Dec 1, 2022 to Jun 30, 2023
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Cape Town
16 trials monitored
See all monitored trials
COPD
1,119 trials monitored
See 34 trials at risk
This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in HIV-infected and HIV-uninfected adults measured by PET/CT.
Trial Details
NCT Number NCT04147286
Lead Sponsor University of Cape Town
Collaborators: University of Zurich, University of Namibia, University of Bern, University of Stellenbosch
Conditions
(from sponsor)		 Tuberculosis, Pulmonary
Related terms Inflammation, Pulmonary Disease, Chronic Obstructive, Tuberculosis, Tuberculosis, Pulmonary
Enrollment 220 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov